-
公开(公告)号:WO2006042034A3
公开(公告)日:2006-04-20
申请号:PCT/US2005/036024
申请日:2005-10-09
Applicant: ABBOTT LABORATORIES , ZHANG, Geoff, G. , BRADLEY, Michael, F. , BARNES, David, M. , HENRY, Rodger
Inventor: ZHANG, Geoff, G. , BRADLEY, Michael, F. , BARNES, David, M. , HENRY, Rodger
IPC: C07D401/14
Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
-
公开(公告)号:WO2006042034A2
公开(公告)日:2006-04-20
申请号:PCT/US2005/036024
申请日:2005-10-09
Applicant: ABBOTT LABORATORIES , ZHANG, Geoff, G. , BRADLEY, Michael, F. , BARNES, David, M. , HENRY, Rodger
Inventor: ZHANG, Geoff, G. , BRADLEY, Michael, F. , BARNES, David, M. , HENRY, Rodger
CPC classification number: C07D401/14 , A61K31/4709 , A61K47/02 , A61K47/12 , C07C31/26
Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Abstract translation: 公开了药物的结晶形式,制备方法,含有它的组合物以及治疗疾病和抑制不利生理事件的方法。
-
公开(公告)号:WO2009039134A1
公开(公告)日:2009-03-26
申请号:PCT/US2008/076592
申请日:2008-09-17
Applicant: ABBOTT LABORATORIES , FLENTGE, Charles, A. , HUTCHINSON, Douglas, K. , BETEBENNER, David, A. , DEGOEY, David, A. , DONNER, Pamela, L. , KATI, Warren, M. , KRUEGER, Allan, C. , LIU, Dachun , LIU, Yaya , LONGENECKER, Kenton, L. , MARING, Clarence, J. , MOTTER, Christopher, E. , PRATT, John, K. , RANDOLPH, John, T. , ROCKWAY, Todd, W. , STEWART, Kent, D. , WAGNER, Rolf , BARNES, David, M. , CHEN, Shuang , FRANCZYK, Thaddeus, S., II , GAO, Yi , HAIGHT, Anthony, R. , HENGEVELD, John, E. , KOTECKI, Brian, J. , LOU, Xiaochun , ZHANG, Geoff, G., Z.
Inventor: FLENTGE, Charles, A. , HUTCHINSON, Douglas, K. , BETEBENNER, David, A. , DEGOEY, David, A. , DONNER, Pamela, L. , KATI, Warren, M. , KRUEGER, Allan, C. , LIU, Dachun , LIU, Yaya , LONGENECKER, Kenton, L. , MARING, Clarence, J. , MOTTER, Christopher, E. , PRATT, John, K. , RANDOLPH, John, T. , ROCKWAY, Todd, W. , STEWART, Kent, D. , WAGNER, Rolf , BARNES, David, M. , CHEN, Shuang , FRANCZYK, Thaddeus, S., II , GAO, Yi , HAIGHT, Anthony, R. , HENGEVELD, John, E. , KOTECKI, Brian, J. , LOU, Xiaochun , ZHANG, Geoff, G., Z.
IPC: C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K31/513 , A61P31/12
CPC classification number: C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及:(a)特别是抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。
-
4.
公开(公告)号:WO2007100990A3
公开(公告)日:2007-09-07
申请号:PCT/US2007/062329
申请日:2007-02-16
Applicant: ABBOTT LABORATORIES , COWART, Marlon, D. , ZHAO, Chen , SUN, Minghua , BLACK, Lawrence, A. , ZHENG, Guo Zhu , GREGG, Robert, J. , ZHANG, Geoff, G.Z. , SHEIKH, Ahmad, Y. , LOU, Xiaochun , HENRY, Rodger, F. , BARNES, David, M. , KOLACZKOWSKI, Lawrence , HAIGHT, Anthony, R. , CHANG, Sou-Jen , WITTENBERGER, Steven, J. , FICKES, Michael, G.
Inventor: COWART, Marlon, D. , ZHAO, Chen , SUN, Minghua , BLACK, Lawrence, A. , ZHENG, Guo Zhu , GREGG, Robert, J. , ZHANG, Geoff, G.Z. , SHEIKH, Ahmad, Y. , LOU, Xiaochun , HENRY, Rodger, F. , BARNES, David, M. , KOLACZKOWSKI, Lawrence , HAIGHT, Anthony, R. , CHANG, Sou-Jen , WITTENBERGER, Steven, J. , FICKES, Michael, G.
IPC: C07D487/04 , A61K31/407
Abstract: Octahydro-pyrrolo[3,4-b]pyrrole derivatives or a pharmaceutically acceptable salt, ester, amide, prodrug, or radiolabeled form thereof, wherein R 1 is alkyl, C 3 -C 5 cycloalkyl. or (C 3 -C 5 cycloalkyl)methyl; R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f each are independently hydrogen, methyl, or fluoromethyl; R 3a , R 3b , R 3c , and R 3d each are independently hydrogen, alkyl, fluoroalkyl, fluoroalkoxy, alkoxy, thioalkoxy, halogen, or nitrile, with the proviso that when one or more of R 3a , R 3b , R 3c , and R 3d are alkyl, then at least one of R 3a , R 3b , R 3c , and R 3d is fluoroalkyl, fluoroalkoxy, alkoxy, thioalkoxy, halogen, or nitrile; L 1 is a bond, oxygen, sulfur, carbonyl, alkylene,. alkylcarbonyl, alkylamino, -C(=N-Oalkyl)-, NR 4 , -C(=O) NR 4 -, or -NR4C(=O)-; R 4 is hydrogen or alkyl; Cy 1 is aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; Z is a substituent R 6 or a group represented by -L 3 -Cy 3 ; R 6 is hydrogen, acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido, carboxy, cyano, cycloalkyl, fiuoroalkoxy, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, alkylthio, amino, NHR 7 , NR 7 R 8 , -N(R 7 )C(=O)R 9 , -C(=O)NR 7 R 8 , or N(R 7 )SO 2 (R 10 ); L 3 is a bond, oxygen, sulfur, carbonyl, alkylene, alkylcarbonyl, alkylamino, -C(=N-Oalkyl)-, NR 11 , -C(=O) NR 11 -, or -NR 11 C(=O)-;Cy 3 is aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; R 7 , R 8 , R 9 , R 10 , and R 11 at each occurrence are independently hydrogen,C 1-4 alkyl, C 3 -C 4 cycloalkyl, or a (C 3 -C 4 cycloalkyl)amine; are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
-
5.
公开(公告)号:WO2004033419A1
公开(公告)日:2004-04-22
申请号:PCT/US2003/031671
申请日:2003-10-06
Applicant: ABBOTT LABORATORIES
Inventor: COMESS, Kenneth, M. , ERICKSON, Scott, A. , HENKIN, Jack , KALVIN, Douglas, M. , KAWAI, Megumi , KIM, Ki, H. , BAMAUNG, Nwe, Y. , PARK, Chan, Hoon , SHEPPARD, George, S. , VASUDEVAN, Anil , WANG, Jieyi , BARNES, David, M. , FIDANZE, Steve, D. , KOLACZKOWSI, Lawrence , MANTEI, Robert, A. , PARK, David, C. , SANDERS, William, J. , TEDROW, Jason, S. , WANG, Gary, T.
IPC: C07C311/08
CPC classification number: C07C323/25 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/37 , C07C311/44 , C07C311/46 , C07C317/28 , C07C323/49 , C07C323/63 , C07C323/67 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/12 , C07D209/08 , C07D209/42 , C07D213/70 , C07D213/71 , C07D215/36 , C07D215/48 , C07D231/18 , C07D233/54 , C07D233/84 , C07D261/10 , C07D285/06 , C07D285/14 , C07D333/34 , C07D333/38 , C07D413/04
Abstract: Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
Abstract translation: 描述了具有甲硫氨酸氨基肽酶-2抑制剂(MetAP2)的化合物。 还描述了包含该化合物的药物组合物,使用该化合物的治疗方法,抑制血管生成的方法和治疗癌症的方法。
-
6.
公开(公告)号:EP1549613A1
公开(公告)日:2005-07-06
申请号:EP03773182.5
申请日:2003-10-06
Applicant: Abbott Laboratories
Inventor: COMESS, Kenneth, M. , ERICKSON, Scott, A. , HENKIN, Jack , KALVIN, Douglas, M. , KAWAI, Megumi , KIM, Ki, H. , BAMAUNG, Nwe, Y. , PARK, Chan, Hoon , SHEPPARD, George, S. , VASUDEVAN, Anil , WANG, Jieyi , BARNES, David, M. , FIDANZE, Steve, D. , KOLACZKOWSKI, Lawrence , MANTEI, Robert, A. , PARK, David, C. , SANDERS, William, J. , TEDROW, Jason, S. , WANG, Gary, T.
IPC: C07C311/08
CPC classification number: C07C323/25 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/37 , C07C311/44 , C07C311/46 , C07C317/28 , C07C323/49 , C07C323/63 , C07C323/67 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/12 , C07D209/08 , C07D209/42 , C07D213/70 , C07D213/71 , C07D215/36 , C07D215/48 , C07D231/18 , C07D233/54 , C07D233/84 , C07D261/10 , C07D285/06 , C07D285/14 , C07D333/34 , C07D333/38 , C07D413/04
Abstract: Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
Abstract translation: 描述了具有甲硫氨酸氨基肽酶-2抑制剂(MetAP2)的化合物。 还描述了包含该化合物的药物组合物,使用该化合物的治疗方法,抑制血管发生的方法和治疗癌症的方法。
-
7.
公开(公告)号:EP1114022A1
公开(公告)日:2001-07-11
申请号:EP99946886.1
申请日:1999-09-13
Applicant: ABBOTT LABORATORIES
Inventor: JI, Jianguo , BARNES, David, M. , KING, Steven, A. , PLAGGE, Frederick, A. , WITTENBERGER, Steven, J. , ZHANG, Ji
IPC: C07C201/12 , C07D317/64 , C07D405/04 , C07D263/52 , C07C251/18
CPC classification number: C07D317/64 , C07D405/04
Abstract: The present invention relates to producing stereoselective nitro compounds by reacting a dicarbonyl compound with a nitrostyrene compound in the presence of a catalyst complex and a base.
-
公开(公告)号:EP2203431B1
公开(公告)日:2011-08-10
申请号:EP08832330.8
申请日:2008-09-17
Applicant: Abbott Laboratories
Inventor: FLENTGE, Charles, A. , HUTCHINSON, Douglas, K. , BETEBENNER, David, A. , DEGOEY, David, A. , DONNER, Pamela, L. , KATI, Warren, M. , KRUEGER, Allan, C. , LIU, Dachun , LIU, Yaya , LONGENECKER, Kenton, L. , MARING, Clarence, J. , MOTTER, Christopher, E. , PRATT, John, K. , RANDOLPH, John, T. , ROCKWAY, Todd, W. , STEWART, Kent, D. , WAGNER, Rolf , BARNES, David, M. , CHEN, Shuang , FRANCZYK, Thaddeus, S., II , GAO, Yi , HAIGHT, Anthony, R. , HENGEVELD, John, E. , KOTECKI, Brian, J. , LOU, Xiaochun , ZHANG, Geoff, G., Z.
IPC: C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K31/513 , A61P31/12
CPC classification number: C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
-
公开(公告)号:EP2001885A2
公开(公告)日:2008-12-17
申请号:EP07757130.5
申请日:2007-02-16
Applicant: ABBOTT LABORATORIES
Inventor: COWART, Marlon, D. , ZHAO, Chen , SUN, Minghua , BLACK, Lawrence, A. , ZHENG, Guo Zhu , GREGG, Robert, J. , ZHANG, Geoff, G.Z. , SHEIKH, Ahmad, Y. , LOU, Xiaochun , HENRY, Rodger, F. , BARNES, David, M. , KOLACZKOWSKI, Lawrence , HAIGHT, Anthony, R. , CHANG, Sou-Jen , WITTENBERGER, Steven, J. , FICKES, Michael, G.
IPC: C07D487/04 , A61K31/407
CPC classification number: C07D487/04
Abstract: Octahydro-pyrrolo[3,4-b]pyrrole derivatives or a pharmaceutically acceptable salt, ester, amide, prodrug, or radiolabeled form thereof, wherein R1 is alkyl, C3-C5 cycloalkyl. or (C3-C5 cycloalkyl)methyl; R2a, R2b, R2c, R2d, R2e, and R2f each are independently hydrogen, methyl, or fluoromethyl; R3a, R3b, R3c, and R3d each are independently hydrogen, alkyl, fluoroalkyl, fluoroalkoxy, alkoxy, thioalkoxy, halogen, or nitrile, with the proviso that when one or more of R3a, R3b, R3c, and R3d are alkyl, then at least one of R3a, R3b, R3c, and R3d is fluoroalkyl, fluoroalkoxy, alkoxy, thioalkoxy, halogen, or nitrile; L1 is a bond, oxygen, sulfur, carbonyl, alkylene,. alkylcarbonyl, alkylamino, -C(=N-Oalkyl)-, NR4, -C(=O) NR4-, or -NR4C(=O)-; R4 is hydrogen or alkyl; Cy1 is aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; Z is a substituent R6 or a group represented by -L3-Cy3; R6 is hydrogen, acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido, carboxy, cyano, cycloalkyl, fiuoroalkoxy, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, alkylthio, amino, NHR7, NR7R8, -N(R7)C(=O)R9, -C(=O)NR7R8, or N(R7)SO2(R10); L3 is a bond, oxygen, sulfur, carbonyl, alkylene, alkylcarbonyl, alkylamino, -C(=N-Oalkyl)-, NR11, -C(=O) NR11-, or -NR11C(=O)-;Cy3 is aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; R7, R8, R9, R10, and R11 at each occurrence are independently hydrogen,C1-4 alkyl, C3-C4 cycloalkyl, or a (C3-C4 cycloalkyl)amine; are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
Abstract translation: 八氢 - 吡咯并[3,4-b]吡咯衍生物或其药学上可接受的盐,酯,酰胺,前药或放射性标记的形式,其中R 1为C 3 -C 5环烷基。 或(C 3 -C 5环烷基)甲基; R2a,R2b,R2c,R2d,R2e和R2f各自独立地为氢,甲基或氟甲基; R3a,R3b,R3c和R3d各自独立地为氢,烷基,氟代烷基,氟代烷氧基,烷氧基,硫代烷氧基,卤素或腈,条件是当R3a,R3b,R3c和R3d中的一个或多个为烷基时, R 3a,R 3b,R 3c和R 3d中的至少一个是氟烷基,氟烷氧基,烷氧基,硫代烷氧基,卤素或腈; L1是一个键,氧,硫,羰基,亚烷基。 (= N-O烷基) - ,NR 4,-C(= O)NR 4 - 或-NR 4 C(= O) - ; R4是氢或烷基; Cy1是芳基,环烷基,环烯基,杂芳基或杂环; Z是取代基R6或由-L3-Cy3表示的基团; 烷基羰基,烷基磺酰基,炔基,酰氨基,羧基,氰基,环烷基,氟代烷氧基,卤代烷氧基,卤代烷基,卤素,羟基,羟基烷基,烷基氨基, 巯基,硝基,烷硫基,氨基,NHR7,NR7R8,-N(R7)C(= O)R9,-C(= O)NR7R8或N(R7)SO2(R10)。 L3是键,氧,硫,羰基,亚烷基,烷基羰基,烷基氨基,-C(= N-O烷基) - ,NR 11,-C(= O)NR 11 - 或-NR 11 C(= O) - ; Cy 3是芳基 ,环烷基,环烯基,杂芳基或杂环; R7,R8,R9,R10和R11各自独立地为氢,C1-4烷基,C3-C4环烷基或(C3-C4环烷基)胺; 可用于治疗由组胺-3受体配体阻止或改善的病症或障碍。 本文公开了八氢 - 吡咯并[3,4-b]吡咯化合物,使用这些化合物的方法,制备它们的组合物以及制备这些化合物的方法。
-
公开(公告)号:EP2203431A1
公开(公告)日:2010-07-07
申请号:EP08832330.8
申请日:2008-09-17
Applicant: Abbott Laboratories
Inventor: FLENTGE, Charles, A. , HUTCHINSON, Douglas, K. , BETEBENNER, David, A. , DEGOEY, David, A. , DONNER, Pamela, L. , KATI, Warren, M. , KRUEGER, Allan, C. , LIU, Dachun , LIU, Yaya , LONGENECKER, Kenton, L. , MARING, Clarence, J. , MOTTER, Christopher, E. , PRATT, John, K. , RANDOLPH, John, T. , ROCKWAY, Todd, W. , STEWART, Kent, D. , WAGNER, Rolf , BARNES, David, M. , CHEN, Shuang , FRANCZYK, Thaddeus, S., II , GAO, Yi , HAIGHT, Anthony, R. , HENGEVELD, John, E. , KOTECKI, Brian, J. , LOU, Xiaochun , ZHANG, Geoff, G., Z.
IPC: C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K31/513 , A61P31/12
CPC classification number: C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
-
-
-
-
-
-
-
-
-